They Scheduled the Cure
How the Justice-Rehabilitation Alliance Criminalized the Most Effective Treatments for Addiction
“I am certain that the LSD experience has helped me very much. I find myself with a heightened
color perception and an appreciation of beauty almost destroyed by my years of depressions.”
- — Bill Wilson, letter to Gerald Heard, 1956*
I. The Founding Irony
In the winter of 1934, a hopeless drunk named Bill Wilson was admitted to Towns Hospital in New York City. He had been there before — twice — and had failed to stay sober each time. On this hospitalization, Dr. William Silkworth administered the standard protocol: a cocktail of belladonna and henbane, both powerful deliriants derived from the nightshade family. Under their influence, Wilson experienced what he later described as a white light filling his room and an ecstasy beyond description. He never drank again.
From this experience, Wilson built Alcoholics Anonymous — a program premised entirely on the necessity of spiritual awakening as the mechanism of recovery. The twelve steps are, at their core, an elaborate architecture designed to produce the same state that belladonna and henbane produced in that hospital room. The problem Wilson identified, and spent the rest of his life trying to solve, is that most suffering alcoholics cannot get there through willpower, prayer, or community alone. They needed what he had been given: a pharmacological key that opened a door the sober mind could not find.
Wilson found that key. He called it LSD. And then the government took it away.
II. Wilson’s Secret
By the mid-1950s, Wilson had befriended philosopher Gerald Heard and Aldous Huxley, who introduced him to Canadian psychiatrists Humphrey Osmond and Abram Hoffer. Osmond and Hoffer were running clinical LSD trials on alcoholics in Saskatchewan with results dramatically superior to AA-alone controls. On August 29, 1956 — LSD still legal, still in clinical use — Wilson took his first dose under the supervision of Dr. Sidney Cohen at the Los Angeles VA Hospital, with Heard as his spiritual guide.
The session notes survive. At 1:00 PM Wilson reported a feeling of peace. By 3:15 PM, an enormous enlargement of everything around him. He wrote to Heard shortly after: “I am certain that the LSD experience has helped me very much. I find myself with a heightened color perception and an appreciation of beauty almost destroyed by my years of depressions.”
Then came the letter to Carl Jung. Near the end of Jung’s life, Wilson wrote to him twice. The first — describing how Jung had told an early AA member that his alcoholism required a spiritual cure (spiritus contra spiritum) — is cited in AA literature. The second, dated March 29, 1961, Wilson largely kept private. In it, he described his LSD experiments in detail: “Some of my AA friends and I have taken the material frequently and with much benefit… a great broadening and deepening and heightening of consciousness.” He told Jung his first session had enacted “with wonderful splendor and conviction” the same mystical revelation he had experienced at Towns Hospital twenty-five years before.
Wilson was telling the father of depth psychology something precise: LSD reliably reproduces the experience that cured me. We should be using it.
His clinical theory was specific. The twelve-step model requires ego dissolution — the temporary suspension of the self-narrative that keeps habitual patterns locked in place. Most alcoholics who achieve lasting recovery through AA experience a sudden, involuntary surrender that breaks this pattern. Wilson called it the spiritual awakening. The problem: most people cannot achieve it deliberately. The ones who succeed in AA are largely those who had it spontaneously — a white light moment of the kind Wilson had at Towns Hospital. LSD, in his formulation, was a preparation tool: a means of producing reliably, in controlled conditions, the same neurological opening that AA waits for and hopes to provoke.
“My friends believe that LSD temporarily triggers a change in blood chemistry that inhibits or reduces ego,” Wilson wrote, “thereby enabling more reality to be felt and seen.” This is not mysticism. It is an early, intuitive description of what neuroscience now calls default mode network deactivation — the mechanism by which psilocybin and LSD produce their therapeutic effects.
Conservative AA leadership rejected it. Members reportedly joked that “Bill takes one pill to see God and another to quiet his nerves.” Wilson never publicly advocated for LSD within AA; he understood that doing so would destroy the institution he had built. He died in 1971, of emphysema from cigarettes — the addiction that, briefly, his 1956 session made him feel he might not need anymore. By then it did not matter. The Controlled Substances Act of 1970 had made the question moot.
III. The Model and Its Capture
The twelve-step framework born from Wilson’s experience — stripped of its psychedelic prehistory, rendered into a program of moral inventory, surrender, and lifetime attendance — became the preferred instrument of the American criminal justice system not because it had the best evidence base, but because it had the most convenient ideology.
Courts have routinely ordered defendants to attend AA and NA meetings as conditions of probation, despite multiple federal rulings establishing that this constitutes an unconstitutional violation of the First Amendment Establishment Clause. Griffin v. Coughlin (1996) and Kerr v. Farrey (1996) both found that twelve-step programs are “intensely religious events” whose mandatory attendance violates the Establishment Clause. The practice continues widely, enabled partly by defendants’ inability to challenge it financially.
The justice system’s preference for this model is structural, not therapeutic. Judges, prosecutors, and probation systems can demonstrate action without addressing causes. Referrals to twelve-step programs cost the state almost nothing. And when people fail and relapse — as most do, because the model’s efficacy is deeply contested — the framework provides a ready explanation: they did not work the steps hard enough. Failure is always the individual’s fault. The system is always blameless.
This logic has been monetized. Companies like GEO Group and CoreCivic — private prison corporations — began acquiring community corrections businesses around 2010, rebranding as rehabilitation providers. A 2015 investor report noted that both companies successfully blocked shareholder resolutions requiring them to spend just 5% of net income on programs to reduce recidivism. The perverse incentive is explicit: these companies generate revenue only as long as they are controlling supervised populations. There is no business case for genuine rehabilitation in a model where more clients means more revenue.
For-profit rehab programs in the private sector mirror this dynamic. Treatment admissions driven by financial incentives rather than clinical necessity produce churn — patients who cycle through expensive programs, relapse, and return — which is profitable for the industry even as it destroys individuals and families. What the system requires, and what it has engineered, is a permanent population of the managed-but-not-fixed.
IV. Individual Pathology as Political Technology
The moral-failing model is not neutral. It is a political technology — a means of locating the source of social harm inside the person rather than in the economic, historical, and structural conditions that produce suffering at scale.
A 2017 report from the National Academy of Sciences concluded that structural factors — lack of economic opportunity, poor working conditions, eroded social capital in depressed communities, hopelessness and despair — are root causes of opioid and substance misuse. Longitudinal research found that adolescents who moved into poverty had hazard ratios of 1.48 for drug use disorder compared to those who were never poor, even after controlling for psychiatric diagnoses and family history. Unemployment, neighborhood vulnerability, trauma, violence, and housing instability consistently escalate substance use; employment, social support, and stable housing facilitate recovery. The determinants are structural. The model is moral.
The twelve-step model is built entirely around personal moral inventory, surrender, and spiritual transformation. The concept of the powerless addict who must surrender to a higher power encodes addiction as a problem of character and soul — not social circumstance. Studies confirm that this discourse shapes how people internally understand their own addiction: subjects in treatment repeatedly frame their experiences through AA and NA slogans, locating blame within themselves rather than in the conditions that produced their use. The moral model operates as both gate and trap — it shames people away from help while simultaneously offering help in the form of moral instruction.
The justice system prefers a model that makes crime derivable from individual pathology: the crime happened because of the addiction; the addiction happened because of the person’s weakness. What goes unasked is why certain communities, certain zip codes, certain economic conditions produce addiction at dramatically higher rates. Asking structural questions would require structural answers. Structural answers implicate the state.
Harvard Law scholarship names the paradox directly: the disease model serves justice’s purposes because it is agency-limiting. An addict defined as sick, broken, or spiritually deficient must be managed, supervised, monitored, and treated — indefinitely. The system needs the illness to be both medical (to justify intervention) and moral (to justify punishment) simultaneously. Sick enough to manage. Guilty enough to punish.
V. The Clinical Evidence
Here is what the criminalized compounds actually do.
Psilocybin-assisted therapy, in a landmark double-blind randomized clinical trial published in JAMA Psychiatry, produced heavy drinking days that were 41% of those in the placebo group over thirty-two weeks of follow-up. NYU Langone researchers found that just two doses of psilocybin reduced heavy drinking by 83% on average among heavy drinkers when combined with psychotherapy. A systematic review of all four clinical trials conducted confirmed beneficial effects on substance use disorder symptoms in every one.
LSD shows a specific, robust signal for alcohol use disorder independent of other psychedelics. Analysis of federal health data found that adults who had used LSD in the past year were 30% less likely to meet criteria for alcohol use disorder and reported approximately 15% fewer AUD symptoms — with neither MDMA nor ketamine showing the same protective link. A Johns Hopkins survey found that after a single psychedelic experience, predominantly LSD or psilocybin, 83% of participants no longer met criteria for severe AUD after an average of seven years of problematic drinking beforehand.
5-MeO-DMT — the active compound in Bufo ceremonies — operates through a distinct pathway: it works primarily by addressing the comorbid psychiatric conditions underneath chronic alcohol use, particularly trauma and depression. A 2024 review found preliminary evidence for its potential in AUD treatment; a real-world case study demonstrated a 75% reduction in PTSD symptoms maintained across a twelve-month follow-up after a single dose. Since untreated trauma is among the primary drivers of chronic alcohol use, this pathway matters structurally, not just clinically.
These compounds are not working through willpower or spiritual surrender. LSD and psilocybin activate serotonin 5-HT2A receptors in ways that reduce the energy needed for the brain to switch between different activity states — making deeply entrenched neural patterns, including compulsive cravings, easier to interrupt and rewire. Psilocin reduces activity in the central amygdala, the stress and fear center that drives emotional drinking. The neurological changes persist long after the drug itself has left the body, which is what makes one or two sessions produce lasting results rather than requiring lifetime maintenance.
Wilson intuited all of this in 1956. He had no neuroscience vocabulary for it. He called it ego dissolution; the default mode network was not named until decades after his death. But his clinical observation was correct: what AA waits years for and hopes will happen spontaneously, psilocybin and LSD produce deliberately, reliably, in a controlled session. The people in AA who get sober through a sudden, profound spiritual experience are experiencing a spontaneous version of what psychedelics produce on demand. For those who never get that spontaneous breakthrough, psychedelics are the reliable shortcut to the same neurological state.
Wilson knew this. He just could not say it out loud without destroying the institution he had built.
VI. They Scheduled the Cure
In 1970, psychedelic research was actively progressing. LSD was already a licensed medicine in some countries. Osmond and Hoffer had been running trials for over a decade. The evidence was accumulating. Then came Nixon and the Controlled Substances Act.
LSD, psilocybin, and mescaline were placed into Schedule I — the most restricted category, nominally reserved for drugs with no medical use and high abuse potential. The criteria are self-fulfilling by design: you cannot prove medical utility if research is legally blocked. And research was blocked. DEA registration requirements, production caps, institutional ethics barriers, and the end of federal funding froze the field for nearly fifty years.
Professor David Nutt, the UK’s leading psychopharmacologist, has stated plainly that psychedelics were banned not on pharmacological grounds but political ones: LSD had become associated with the anti-Vietnam War movement, Nixon needed the drug war for re-election, and manufactured scare stories buried two decades of clinical evidence. MAPS has documented how, once the Act passed, psychedelic researchers across the country immediately discontinued all studies — not because the science was bad, but because continuing had become legally and professionally untenable.
The classification was never pharmacologically honest. As recently as 2023, the DEA proposed scheduling two additional psychedelic research compounds — DOI and DOC — as Schedule I without any evidence of actual abuse, purely by analogy to other psychedelics. A Senate committee in 2025 formally expressed concern that Schedule I restrictions “effectively limit the amount and type of research” on psychedelics. The barrier is not science. It never was.
There is also the off-patent problem. Psilocybin, LSD, and DMT are natural compounds with expired or inapplicable patents. Pharmaceutical companies have little economic incentive to seek DEA approval for clinical psychedelic research because even if they prove efficacy, anyone can produce the compound. The current pharmacotherapy industry — naltrexone, acamprosate, Vivitrol — generates recurring revenue from chronic-use models. A treatment that produces lasting remission from one or two sessions is the worst possible business model for an industry built on lifetime management.
The architecture is complete. A drug war that classified the most promising treatments as having no medical value. A legal structure that makes research prohibitively expensive. A pharmaceutical industry with no profit motive to fund it. A recovery industrial complex whose entire revenue model depends on people not getting cured. This is not a system that failed to solve addiction. It is a system that solved its own problem, which was never addiction.
VII. The Revenue Model Requires the Unfixed
Emerging pharmacology is now threatening the architecture from two directions simultaneously.
GLP-1 receptor agonists — semaglutide, tirzepatide, the same drugs driving the obesity and diabetes market — are showing striking results in alcohol use disorder research. A 2026 randomized controlled trial found that semaglutide produced meaningful reductions in heavy drinking days, overall consumption, and subjective cravings compared to placebo, the first direct human evidence that GLP-1 drugs translate into behavioral improvements in AUD. The Endocrine Society describes GLP-1s as modulating neurobiological pathways underlying addictive behaviors — acting directly on appetite and reward centers with effects extending beyond food to alcohol and other drugs.
Unlike psilocybin and LSD, GLP-1 agonists are on-patent, profitable, and already in widespread clinical use. They cannot be scheduled. They are arriving through the front door of mainstream medicine, and their mechanism — direct modulation of the brain’s reward architecture — makes the same fundamental claim that psychedelics make: addiction is a neurobiological condition addressable through pharmacology, not a moral deficit addressable through inventory and surrender.
This convergence — psychedelics from one direction, GLP-1s from another, structural epidemiology from a third — is beginning to make the individual-failing model untenable not just morally but empirically. The model persists not because it is true but because it is institutionally convenient, politically inoffensive, and because it never threatens to expose the structural failures that produce mass addiction in the first place.
For-profit corrections corporations blocking recidivism reduction. Courts mandating a religious program in violation of the First Amendment. Fifty years of clinical research frozen by a political classification. An off-patent problem ensuring the most effective treatments are also the least profitable. None of this is accident. It is the system working as designed.
VIII. Conclusion
Bill Wilson had the experience that founded AA because a physician gave him belladonna and henbane. He spent the last fifteen years of his life quietly accumulating evidence that LSD could reliably produce the same experience for the alcoholics his own program was failing. He was right. The evidence now is unambiguous.
The Controlled Substances Act of 1970 did not know and did not care that it was scheduling the mechanism of AA’s own founding. It knew, and cared, that LSD had become associated with the movement against the Vietnam War and that the drug war was electorally useful. The science was a casualty of the politics. The casualties of the science are measured in lives.
The system that mandates twelve-step attendance as a condition of probation is the same system that criminalized the compounds that make twelve-step unnecessary for a significant proportion of suffering people. It medicalizes addiction enough to justify diversion into treatment — and all the profit and surveillance that entails — but never enough to remove criminal responsibility or permit the treatments with the strongest evidence. The illness must be both medical and moral simultaneously. The person must be sick enough to manage and guilty enough to punish.
They scheduled the cure. The question now is not whether we know this. It is whether the knowledge is actionable — whether the converging pressure of pharmacological evidence, structural research, and Schedule I reform can finally break the alliance between punishment and profit that has shaped addiction policy for fifty years.
The research says yes. The revenue model says otherwise.